Skip to main content
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1982 Dec;41(6):557–562. doi: 10.1136/ard.41.6.557

Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases.

P Hollingworth, A de Vere Tyndall, B M Ansell, T Platts-Mills, J M Gumpel, J Mertin, D S Smith, A M Denman
PMCID: PMC1000984  PMID: 6128961

Abstract

Intensive immunosuppression (IIS) was compared with prednisolone alone over a 2-year period in the treatment of severe connective tissue diseases. IIS consisted of 15 daily infusions of 750 mg antilymphocyte globulin (ALG), azathioprine 2.5 mg/kg/day, and prednisolone reducing from 150 mg, followed by maintenance azathioprine and prednisolone. The initial dose for prednisolone by itself was 60 mg and patients not responding to this regimen over a minimum of one month were then given IIS. Forty-one patients with life-threatening or severely disabling polyarteritis nodosa (PAN), dermatomyositis/polymyositis (DM), or systemic lupus erythematosus received one or other treatment. All 11 patients who received IIS for PAN remitted. Ten of these had renal impairment which was reversed or halted with IIS, and in 6 of these renal function had been deteriorating with prednisolone alone. One patient died of pneumonia in renal failure 9 months later but with PAN in remission. Two further patients, neither having renal involvement, achieved remission with prednisolone alone. Early cytotoxic treatment would seem to be indicated in PAN when there is renal involvement. Two patients with DM entered remission or prednisolone alone. The remaining 12, of whom 5 had failed steroid therapy, received IIS. Improvement or halting of deterioration was achieved in all 12 with best results in those without marked muscle wasting consequent to disease of long duration. The results suggest that IIS may be a useful adjunct in those patients failing to respond to prednisolone. IIS seemed no more effective than prednisolone alone in the treatment of the 14 patients with SLE and in particular lupus nephritis. Flares in disease activity were common in both groups and appeared to be related to prednisolone dosage. IIS was generally well tolerated, though infection occurred in 2 patients. Vertebral collapse or osteonecrosis of the femoral head occurred in 3 patients following IIS, all of whom had been previously receiving prednisolone for long periods.

Full text

PDF
557

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bohan A., Peter J. B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 Feb 13;292(7):344–347. doi: 10.1056/NEJM197502132920706. [DOI] [PubMed] [Google Scholar]
  2. Bunch T. W. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 1981 Jan;24(1):45–48. doi: 10.1002/art.1780240107. [DOI] [PubMed] [Google Scholar]
  3. Cohen R. D., Conn D. L., Ilstrup D. M. Clinical features, prognosis, and response to treatment in polyarteritis. Mayo Clin Proc. 1980 Mar;55(3):146–155. [PubMed] [Google Scholar]
  4. Devita V. T., Jr, Serpick A. A., Carbone P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970 Dec;73(6):881–895. doi: 10.7326/0003-4819-73-6-881. [DOI] [PubMed] [Google Scholar]
  5. Donadio J. V., Jr, Holley K. E., Ferguson R. H., Ilstrup D. M. Progressive lupus glomerulonephritis. Treatment with prednisone and combined prednisone and cyclophosphamide. Mayo Clin Proc. 1976 Aug;51(8):484–494. [PubMed] [Google Scholar]
  6. Donadio J. V., Jr, Holley K. E., Wagoner R. D., Ferguson R. H., McDuffie F. C. Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Arthritis Rheum. 1974 Sep-Oct;17(5):573–581. doi: 10.1002/art.1780170511. [DOI] [PubMed] [Google Scholar]
  7. Fauci A. S., Katz P., Haynes B. F., Wolff S. M. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med. 1979 Aug 2;301(5):235–238. doi: 10.1056/NEJM197908023010503. [DOI] [PubMed] [Google Scholar]
  8. Ginzler E., Diamond H., Guttadauria M., Kaplan D. Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis. Arthritis Rheum. 1976 Jul-Aug;19(4):693–699. doi: 10.1002/1529-0131(197607/08)19:4<693::aid-art1780190406>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  9. Haas D. C. Treatment of polymyositis with immunosuppressive drugs. Neurology. 1973 Jan;23(1):55–62. doi: 10.1212/wnl.23.1.55. [DOI] [PubMed] [Google Scholar]
  10. Hahn B. H., Kantor O. S., Osterland C. K. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients. Ann Intern Med. 1975 Nov;83(5):597–605. doi: 10.7326/0003-4819-83-5-597. [DOI] [PubMed] [Google Scholar]
  11. Melam H., Patterson R. Periarteritis nodosa. A remission achieved with combined prednisone and azathioprine therapy. Am J Dis Child. 1971 May;121(5):424–427. [PubMed] [Google Scholar]
  12. Metzger A. L., Bohan A., Goldberg L. S., Bluestone R., Pearson C. M. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med. 1974 Aug;81(2):182–189. doi: 10.7326/0003-4819-81-2-182. [DOI] [PubMed] [Google Scholar]
  13. Schwarz H. A., Slavin G., Ward P., Ansell B. M. Muscle biopsy in polymyositis and dermatomyositis: a clinicopathological study. Ann Rheum Dis. 1980 Oct;39(5):500–507. doi: 10.1136/ard.39.5.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Steinberg A. D., Kaltreider H. B., Staples P. J., Goetzl E. J., Talal N., Decker J. L. Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med. 1971 Aug;75(2):165–171. doi: 10.7326/0003-4819-75-2-165. [DOI] [PubMed] [Google Scholar]
  15. Sztejnbok M., Stewart A., Diamond H., Kaplan D. Azathioprine in the treatment of systemic lupus erythematosus. A controlled study. Arthritis Rheum. 1971 Sep-Oct;14(5):639–645. doi: 10.1002/art.1780140511. [DOI] [PubMed] [Google Scholar]
  16. Wechter W. J., Brodie J. A., Morrell R. M., Rafi M., Schultz J. R. Antithymocyte globulin (ATGAM) in renal allograft recipients. Multicenter trials using a 14-dose regimen. Transplantation. 1979 Oct;28(4):294–302. doi: 10.1097/00007890-197910000-00006. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES